147 related articles for article (PubMed ID: 17579978)
21. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
[TBL] [Abstract][Full Text] [Related]
22. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
23. The benefit of individualized low-dose hCG support for high responders in GnRHa-triggered IVF/ICSI cycles.
Huang CY; Shieh ML; Li HY
J Chin Med Assoc; 2016 Jul; 79(7):387-93. PubMed ID: 27147462
[TBL] [Abstract][Full Text] [Related]
24. Symposium: Update on prediction and management of OHSS. Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation.
Kol S; Dor J
Reprod Biomed Online; 2009 Jul; 19(1):59-60. PubMed ID: 19573291
[TBL] [Abstract][Full Text] [Related]
25. Total ovarian volume before human chorionic gonadotrophin administration for ovulation induction may predict the hyperstimulation syndrome.
Oyesanya OA; Parsons JH; Collins WP; Campbell S
Hum Reprod; 1995 Dec; 10(12):3211-12. PubMed ID: 8822446
[TBL] [Abstract][Full Text] [Related]
26. 'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome.
Egbase PE; Al-Sharhan M; Grudzinskas JG
Hum Reprod; 2002 May; 17(5):1212-6. PubMed ID: 11980740
[TBL] [Abstract][Full Text] [Related]
27. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
Araujo E; Bernardini L; Frederick JL; Asch RH; Balmaceda JP
J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
[TBL] [Abstract][Full Text] [Related]
28. Induction of pre-ovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome.
Shalev E; Geslevich Y; Ben-Ami M
Hum Reprod; 1994 Mar; 9(3):417-9. PubMed ID: 8006128
[TBL] [Abstract][Full Text] [Related]
29. Symposium: Update on prediction and management of OHSS. Prevention of OHSS.
Aboulghar M
Reprod Biomed Online; 2009 Jul; 19(1):33-42. PubMed ID: 19573288
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
[TBL] [Abstract][Full Text] [Related]
31. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
Zhu YM; Gao HJ; He RH; Huang HF
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
[TBL] [Abstract][Full Text] [Related]
32. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome.
Mathur R; Kailasam C; Jenkins J
Hum Fertil (Camb); 2007 Jun; 10(2):75-85. PubMed ID: 17564886
[TBL] [Abstract][Full Text] [Related]
33. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
[TBL] [Abstract][Full Text] [Related]
34. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose.
Kashyap S; Parker K; Cedars MI; Rosenwaks Z
Semin Reprod Med; 2010 Nov; 28(6):475-85. PubMed ID: 21082506
[TBL] [Abstract][Full Text] [Related]
35. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
36. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.
Lyons CA; Wheeler CA; Frishman GN; Hackett RJ; Seifer DB; Haning RV
Hum Reprod; 1994 May; 9(5):792-9. PubMed ID: 7929724
[TBL] [Abstract][Full Text] [Related]
37. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
Radesic B; Tremellen K
Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
[TBL] [Abstract][Full Text] [Related]
38. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
[TBL] [Abstract][Full Text] [Related]
39. Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome.
Johnson MD; Williams SL; Seager CK; Liu JH; Barker NM; Hurd WW
Gynecol Endocrinol; 2014 Apr; 30(4):294-7. PubMed ID: 24455971
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.
Delvigne A; Rozenberg S
Hum Reprod Update; 2002; 8(6):559-77. PubMed ID: 12498425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
